Loading...
With the introduction of linezolid in 2000, an alternative to vancomycin became available for treatment of infections caused by multidrug-resistant gram-positive pathogens, particularly methicillin-resistant Staphylococcus aureus (MRSA). A recent comparison between linezolid and vancomycin for treatment of pneumonia (see Journal Watch Infectious Diseases Mar 12 2004) showed a nonsignificant trend favoring linezolid, with the difference being most pronounced in MRSA pneumonia. Now, in an industry-sponsored, multinational, multicenter, randomized trial, researchers have compared these drugs in 1180 patients with complicated skin and soft-tissue infections.
In intent-to-treat analyses, clinical cure rates were nonsignificantly better with linez…